With political action underway through an executive order from President Donald Trump and pharmaceutical industry shifts emerging, the question remains whether these changes will lead to sustained ...

Since President Donald J. Trump took office a second time on Jan. 20, leaders across the biotechnology and pharmaceutical ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

The test can aid doctors in determining whether a patient's memory problems are due to Alzheimer's or a number of other ...

Providers of compounded obesity drugs are finding—for now—a new way into the booming market by tweaking formulations.

The head of drugmaker Eli Lilly, which sells the popular weight ... right mechanism” to bolster U.S. drug manufacturing, Lilly Chief Executive David Ricks said on a conference call with analysts ...

Even before the Trump administration’s executive order wiping out the concept of diversity, equity and inclusion, the statistics on female representation in the biotech industry painted a story of ...

The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market ...

Novo Nordisk, the company that makes Wegovy and Ozempic, is abruptly ousting its chief executive over concerns the firm is losing ground in the popular weight-loss drug market. The firm's market value ...

Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing ...

Novo Nordisk said Friday it will replace its CEO, citing a sharp tumble for Novo shares amid growing competition.